SCHEMBL2925799

SCHEMBL2925799

CS(=O)(=O)c1cnc2c(cc(-c3ncco3)n2Cc2ccc(F)cc2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 17/20 0.38
CYP1A2 P05177 16/20 0.38
CYP2C19 P33261 13/20 0.38
USP2 O75604 13/20 0.38
TSHR P16473 12/20 0.38
ALDH1A1 P00352 10/20 0.38
LMNA P02545 3/20 0.38
CYP2C9 P11712 14/20 0.38
HSD17B10 Q99714 5/20 0.37
HPGD P15428 5/20 0.37
CASP1 P29466 4/20 0.37
CASP7 P55210 2/20 0.37
ADORA1 P30542 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
CYP2D6 P10635 1/20 0.37
MAPK1 P28482 9/20 0.36
HIF1A Q16665 5/20 0.36
GLA P06280 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
SMN1; SMN2 Q16637 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2925246 0.83 PTGS2 (0.41) CYP3A4CYP1A2CYP2C19USP2TSHR
SCHEMBL2921880 0.80 CYP1A2 (0.38) CYP3A4CYP1A2CYP2C19USP2TSHR
SCHEMBL13628863 0.78 CYP1A2 (0.38) CYP3A4CYP1A2CYP2C19USP2TSHR
SCHEMBL2926933 0.76 CCR9 (0.41) CYP3A4CYP1A2CYP2C19USP2TSHR
SCHEMBL2921287 0.75 CYP3A4 (0.40) CYP3A4CYP1A2CYP2C19USP2TSHR
SCHEMBL2931092 0.74 MAPT (0.47) CYP3A4CYP1A2CYP2C19USP2TSHR
SCHEMBL13628822 0.72 CYP1A2 (0.37) CYP3A4CYP1A2CYP2C19USP2TSHR
SCHEMBL2922100 0.69 CNR2 (0.42) CYP3A4CYP1A2CYP2C19USP2TSHR
SCHEMBL2922392 0.67 CNR2 (0.46) ADORA1PTGS2
SCHEMBL2921345 0.66 PTGS2 (0.43) CYP3A4CYP1A2CYP2C19USP2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1086950-B1 HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES CHUGAI PHARMACEUTICAL CO LTD (JP) 2010-09-29 EP claimed
US-7612070-B2 Heterocyclic compounds as antiinflammatory agents and cyclooxygenase inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-11-03 US claimed
US-20050137202-A1 Indole derivative having heterocycle and mono- or diazaindole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-06-23 US claimed
EP-1086950-A1 HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2001-03-28 EP claimed
EP-1086950-B1 HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES CHUGAI PHARMACEUTICAL CO LTD (JP) 2010-09-29 EP disclosed
EP-1086950-B1 HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES CHUGAI PHARMACEUTICAL CO LTD (JP) 2010-09-29 EP disclosed
US-7612070-B2 Heterocyclic compounds as antiinflammatory agents and cyclooxygenase inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-11-03 US disclosed
US-7612070-B2 Heterocyclic compounds as antiinflammatory agents and cyclooxygenase inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-11-03 US disclosed
US-20050137202-A1 Indole derivative having heterocycle and mono- or diazaindole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-06-23 US disclosed
US-6875770-B2 Indole derivative having heterocycle and mono- or diazaindole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-04-05 US disclosed
US-20040067964-A1 Indole derivative having heterocycle and mono- or diazaindole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-04-08 US disclosed
US-6673797-B1 CYCLOOXYGENASE-2 INHIBITORS; TREATING INFLAMMATORY DISEASE INDUCED BY CYCLOOXYGENASE-2 CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-01-06 US disclosed
EP-1086950-A1 HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137202-A1 Indole derivative having heterocycle and mono- or diazaindole derivative PTGS2, IDO2, IDO1 CYP3A4 77/4885CYP1A2 22/4885CYP2C19 60/4885
US-20040067964-A1 Indole derivative having heterocycle and mono- or diazaindole derivative IDO1, PTGS1, IDO2 CYP3A4 58/4885CYP1A2 18/4885CYP2C19 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.